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Background. Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities
after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of
thrombocytopenia in patients undergoing PCI is largely unknown. The aim of this study was to evaluate the influence of
baseline thrombocytopenia on the prognosis of patients undergoing PCI. Methods. Using the West China Hospital Inpatient
Sample database, patients who underwent PCI were identified from August 2012 to January 2019. Baseline thrombocytopenia
was defined as a preprocedural platelet count of 100 × 109/L or less obtained from a routine blood sample taken within 48 hours
before coronary PCI. The clinical effect of the advanced thrombocytopenia group (≤85 × 109/L), according to the median value
of platelet count in the thrombocytopenia cohort, was further assessed. The primary outcome was a composite of in-hospital
death, bleeding events, and post-PCI transfusion. Results. Of 9531 patients enrolled in our study, 936 had baseline
thrombocytopenia and 8595 patients did not have. There were no significant differences in the primary outcome between the
two groups. However, advanced thrombocytopenia was independently associated with higher risk of primary outcome (OR 1.67,
95% CI 1.06 to 2.65, p = 0:029). Acute coronary syndrome (ACS) patients with thrombocytopenia were associated with higher
odds of major bleeding (BARC ≥ 2) (OR 2.56, 95% CI 1.24 to 5.44, p = 0:011). Compared with the nonthrombocytopenia group,
the thrombocytopenia group with ticagrelor use had higher odds of major bleeding (OR 9.7, 95% CI 1.57 to 60.4 versus OR
0.22, 95% CI 0.03 to 1.69, interaction p = 0:025). Conclusions. It seems feasible for patients with thrombocytopenia to receive
PCI, but close attention should be paid to advanced thrombocytopenia, the risk of postprocedure bleeding in ACS patients, and
the use of more potent P2Y12 inhibitor.
1. Introduction
The management of antiplatelet therapy/percutaneous coro-
nary intervention (PCI) in coronary artery disease (CAD)
patients with thrombocytopenia poses a particular challenge
for physicians, as they are at higher risk of both bleeding and,
paradoxically, ischemic events [1]. The reported incidence of
baseline thrombocytopenia was varied approximately from
1% to 13% of CAD patients [2, 3]. However, these patients
have almost invariably been excluded from randomized clin-
ical trials of PCI or antithrombotic therapies [4, 5]. No guide-
lines and only several reports are available on the safety and
tolerance of antiplatelet therapy/PCI in CAD patients com-
plicated with thrombocytopenia at baseline, and the results
are still controversial. Previous studies revealed that patients
with baseline thrombocytopenia had higher risk for bleeding
events and death [3, 6], while no differences in mortality or
bleeding complications between PCI patients with and with-
out thrombocytopenia were also demonstrated [2, 7, 8].
Hence, the real impact of thrombocytopenia in patients
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undergoing PCI is largely unknown. Therefore, this large
cohort study was aimed at evaluating the effect of baseline
thrombocytopenia on the prognosis of patients undergoing
PCI according to the current practice.
2. Materials and Methods
2.1. Study Design and Subjects. This retrospective cohort
study included 13,920 consecutively enrolled CAD patients
with PCI from August 1, 2012, to January 30, 2019, at West
China Hospital. The study protocol was approved by the
Ethics Committee of West China Hospital of Sichuan Univer-
sity (Sichuan, China). 3733 patients without complete blood
count analysis before PCI were excluded. For patients with
multiple PCI procedures, only the first PCI in the time period
was included, leaving 9531 patients for analysis (Figure 1). For
the purpose of this study, baseline thrombocytopenia was
defined as a preprocedural platelet count of 100 × 109/L or less
obtained from a routine blood sample taken within 48 hours
before coronary PCI. The thrombocytopenia cohort was fur-
ther classified into patients with intermediate thrombocytope-
nia (85 × 109/L < platelet count ≤ 100 × 109/L) and advanced
thrombocytopenia (≤85 × 109/L) according to the median
value of platelet count of this thrombocytopenia group.
2.2. Data Collection. Clinical data were extracted from the
Hospital Information System and obtained through a review
of medical records. Baseline characteristics, medical history,
comorbidities, and in-hospital management based on pre-
scription records were evaluated by experienced cardiolo-
gists. Laboratory test results of enrolled subjects performed
in the West China Hospital Biochemistry Laboratory were
also collected.
2.3. Clinical Outcomes. The primary outcome was a compos-
ite of in-hospital all-cause death, bleeding events, and post-
PCI transfusion. Secondary outcomes included major
adverse cardiovascular events (MACE); a composite of in-
hospital cardiac mortality, myocardial infarction (MI), target
vessel revascularization (TVR), or stent thrombosis; ischemic
and hemorrhagic cerebrovascular accident (CVA); and
length of stay. The Bleeding Academic Research Consortium
(BARC) definition for bleeding was used to describe bleeding
events [9]. Major bleeding was categorized as type 2, 3, or 5
(type 2 indicating any overt, actionable sign of bleeding; type
3 indicating bleeding with a decrease in the hemoglobin of
>3 g per deciliter, any transfusion, cardiac tamponade, or
intracranial or ocular involvement; and type 5 indicating fatal
bleeding). The MACE endpoints were defined in accordance
with the Academic Research Consortium (ARC) definitions
[10]. MI was defined according to the third Universal Defini-
tion of MI [11]. For PCI-related MI, we used higher bio-
marker thresholds for confirmation according to the
ISCHEMIA trial (International Study of Comparative Health
Effectiveness with Medical and Invasive Approaches) [12].
Cardiac mortality was defined as a documented arrhythmo-
genic death, an unexpected presumed pulseless condition
with the absence of an obvious noncardiac explanation, or
death due to congestive cardiac failure or structural heart
disease. CVA was defined as an acute episode of focal or
global neurological dysfunction persisting for more than 24
hours or leaving residual signs and confirmed by skull CT
or MRI. Hospital records were searched for all keywords
associated with potential bleeding events, including bleeding
and transfusion, and a review of medical records. Outcomes
were interpreted and judged by an independent cardiologist.
2.4. Statistical Analysis. There were no missing data for the
included variables. Some variables with missing data, such
as estimated glomerular filtration rate and left ventricular
ejection fraction, were not included in our study. All analyses
were performed with SPSS version 23 (IBM Corporation,
Armonk, NY). Continuous variables were expressed as
mean ± standard deviation or median with 25th and 75th
interquartile range and were compared using the Student t
-test or Wilcoxon rank-sum test depending on their distribu-
tions. Categorical variables were presented as number and
percentage and were compared with the χ2 or Fisher exact
test. Differences in outcomes were reported as odds ratios
(OR) with 95% confidence intervals (CI). To address the pos-
sible imbalance in the participants’ characteristics between
the test groups, a propensity score approach was used. The
propensity score predicting thrombocytopenia was generated
using multivariable logistic regression with thrombocytope-
nia as the dependent variable and fifteen prespecified baseline
characteristics and traditional risk factors (age, sex, hyperten-
sion, diabetes mellitus, atrial fibrillation, hyperlipidemia,
congestive heart failure, chronic kidney disease, chronic liver
disease, prior cerebrovascular accident, prior PCI, prior
CABG, stents placed (≥2), use of intra-aortic balloon pump,
and arterial approach) as the independent variables. Logistic
regression was performed to identify the association between
thrombocytopenia and the risk of clinical outcomes. We used
the propensity score as a control variable in the covariate-
adjusted analysis of the outcome variables [13]. The associa-
tion between thrombocytopenia and lg10-transformed
length of stay (due to lack of normality) was assessed by lin-
ear regression analysis. All reported p values were 2-tailed,
and p values < 0.05 were considered statistically significant.
3. Results
3.1. Baseline Characteristics. Of 9531 PCI procedures, 936
patients (9.8%) had thrombocytopenia at baseline. The
median platelet count in patients with thrombocytopenia
was 85 × 109/L (25th, 75th percentiles, 74 × 109/L, 94 × 109/
L; range, 6 to 100 × 109/L). All PCI patients used a second-
generation drug-eluting stent, and approximately 95% of
the stent type was Promus PREMIER™ (MONORAIL™, Bos-
ton Scientific, USA) and 5% was GuReater® (CoCr
Sirolimus-Eluting Coronary Stent System, LEPU MEDICAL,
China). Compared with patients without thrombocytopenia,
patients with thrombocytopenia were older, were more com-
monly men, had higher level of creatinine and total bilirubin,
and had a higher prevalence of atrial fibrillation, chronic kid-
ney disease, and chronic liver disease and lesser use of aspirin
(Table 1).
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3.2. In-Hospital Clinical Outcomes. Compared with PCI
patients without thrombocytopenia, patients with thrombo-
cytopenia had higher prevalence of primary outcome (4.0%
vs. 2.5%, p = 0:009), including higher prevalence of major
bleeding (BARC ≥ 2) (1.3% vs. 0.6%, p = 0:014) and transfu-
sion (1.9% vs. 1.0%, p = 0:016). No significant difference in
the secondary outcome was detected between the groups,
while the thrombocytopenia cohort had higher prevalence
of TVR (0.3% vs. 0.1%, p = 0:042). Patients with thrombocy-
topenia had longer length of hospital stay (5 (3–7) days vs. 4
(3–6) days, p = 0:007). After adjusting for the propensity
scores in a logistic or linear regression model, thrombocyto-
penia showed no effects on the rates of primary and second-
ary outcomes except that thrombocytopenia was associated
with higher risk of TVR (OR 4.93, 95% CI 1.13 to 21.46, p
= 0:03) (Table 2). Additionally, compared with PCI patients
with intermediate thrombocytopenia, the rate of primary
outcome, including major bleeding (BARC ≥ 2) and transfu-
sion, was significantly higher in the PCI cohort with
advanced thrombocytopenia (Supplemental Table 1). After
adjusting for the propensity scores in a logistic regression
model, advanced thrombocytopenia was associated with
higher risk of primary outcome (OR 1.67, 95% CI 1.06 to
2.65, p = 0:029), including higher risk of major bleeding
(OR 2.35, 95% CI 1.11 to 5.00, p = 0:027) and transfusion
(OR 2.16, 95% CI 1.17 to 4.00, p = 0:014) (Table 3).
3.3. Clinical Outcomes in Patients with Acute Coronary
Syndrome. Compared with acute coronary syndrome (ACS)
patients without thrombocytopenia, ACS patients with
thrombocytopenia had higher prevalence of primary out-
come (5.4% vs. 3.1%, p = 0:007), including higher prevalence
of all-cause mortality (2.6% vs. 1.3%, 8), bleeding (2.4% vs.
1.2%, p = 0:024), major bleeding (BARC ≥ 2) (2.2% vs.
0.7%, p = 0:001), and transfusion (2.6% vs. 1.4%, p = 0:027).
No significant difference in the secondary outcome was
detected between the groups (Table 4). After adjusting for
the propensity scores, ACS patients with thrombocytopenia
were only associated with higher risk of major bleeding
(BARC ≥ 2) (OR 2.56, 95% CI 1.24 to 5.44, p = 0:011), while
there were no effects on the rates of other in-hospital
outcomes. There were no significant differences in clinical
outcomes in the chronic coronary syndrome cohort with or
without thrombocytopenia (Supplemental Table 2).
3.4. Clinical Outcomes Stratified by Usage of Ticagrelor. Spe-
cifically, among patients who received more potent P2Y12
inhibitor (ticagrelor), we determined if there was variability
in ticagrelor-associated outcomes in PCI patients with
thrombocytopenia. As shown in Figure 2, there were no sig-
nificant differences in the treatment effect of ticagrelor in
rates of primary outcome in patients with thrombocytopenia
(OR 2.10, 95% CI 0.50 to 8.83) or without thrombocytopenia
(OR 1.28, 95% CI 0.74 to 2.23, interaction p = 0:83). Likewise,
no statistical evidence of heterogeneity was found between
the thrombocytopenia and nonthrombocytopenia cohorts
for the secondary outcome. However, compared with the
nonthrombocytopenia group, we did observe higher odds
of bleeding (OR 6.48, 95% CI 1.12 to 37.66 versus OR 0.92,
95% CI 0.36 to 2.38, interaction p = 0:08) and major bleeding
(OR 9.7, 95% CI 1.57 to 60.4 versus OR 0.22, 95% CI 0.03 to
1.69, interaction p = 0:025) in the thrombocytopenia group
with ticagrelor use.
4. Discussion
Several important findings were observed in this large retro-
spective study of contemporary domestic real-world clinical
practices of PCI and periprocedural antithrombotic use
among 9531 CAD patients from over approximately 8 years
from 2012 to 2019. Firstly, the incidence of baseline throm-
bocytopenia in patients undergoing PCI was common,
occurring in approximately one in ten patients. Secondly,
although there is high prevalence of baseline thrombocytope-
nia, the incidence of in-hospital adverse events did not
increase significantly in the thrombocytopenia group when
compared with the normal platelet group. However,
advanced thrombocytopenia was independently associated
with higher risk of the primary outcome. Thirdly, thrombo-
cytopenia in the ACS subgroup was associated with higher
risk of in-hospital major bleeding, while there were no effects
on the rates of all-cause mortality, cardiac mortality, CVA,
and transfusion and on the length of hospital stay. Fourthly,
higher risks of bleeding or major bleeding were observed
when ticagrelor was used in thrombocytopenia patients.
CAD patients undergoing PCI between Aug 2012 to Jan 2019
(n = 13,920) 
Patients met final criteria (n = 9,531) 
Exclusion: 
(i) Baseline platelet count not available
(n = 3,733)
(ii) With multiple PCI procedures (n = 656) 
With baseline
thrombocytopenia (n = 936)
Without baseline
thrombocytopenia (n = 8,595)
Figure 1: Study flowchart describing inclusion and exclusion criteria leading to the final cohort of patients. CAD: coronary artery disease;
PCI: percutaneous coronary intervention.
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Our results are consistent with Raphael et al.’s [8] and Liu
et al.’s [2] findings. In Raphael et al.’s retrospective analysis
(thrombocytopenia was defined as platelet count < 100 × 109/
L, n = 204), in-hospital bleeding events and death after PCI
were similar in patients with and without thrombocytopenia.
Although a higher number of bleeding events in the thrombo-
cytopenia group were detected on follow-up, this phenomenon
happened at 5 years after PCI and was largely gastrointestinal
in nature, unrelated to the PCI procedure and dual antiplatelet
therapy. Liu et al.’s study was aimed at investigating the long-
term impact of thrombocytopenia (defined as platelet count
< 150 × 109/L, n = 1263) in Chinese patients undergoing
elective PCI. No differences in 30-month adverse outcomes,
including mortality and bleeding complications, were detected
between patients with and without thrombocytopenia. Addi-
tionally, in cancer patients with ACS and chronic thrombocy-
topenia, no procedure- or antiplatelet therapy-related
cerebrovascular events were noted. Moderate thrombocytope-
nia was associated with decreased overall survival, whereas
aspirin, dual antiplatelet therapy, and statin use showed a trend
of improved overall survival [14]. These results indicated that
it seemed feasible for patients withmoderate chronic thrombo-
cytopenia to receive PCI as well as guideline-recommended
duration of antiplatelet therapy.
Table 1: Demographic and clinical characteristics of patients with and without thrombocytopenia.
Variable With TCP (n = 936) Without TCP (n = 8595) p value
Mean age (yrs) 67:1 ± 10:2 64:6 ± 11:5 <0.001
Male, n (%) 758 (81.0) 6614 (77.0) 0.005
Platelet (×109/L) 85 (74–94) 174 (141–215) <0.001
Creatinine (μmol/L) 85 (72–103) 81 (69–95) <0.001
Total bilirubin (μmol/L) 13.1 (9.8–17.2) 10.9 (8.0–14.8) <0.001
Hypertension, n (%) 514 (54.9) 4949 (57.6) 0.12
Diabetes mellitus, n (%) 273 (29.2) 2409 (28.0) 0.46
Atrial fibrillation, n (%) 54 (5.8) 332 (3.9) 0.005
Hyperlipidemia, n (%) 68 (7.2) 714 (8.3) 0.27
Chronic kidney disease, n (%) 55 (5.9) 316 (3.7) 0.001
Chronic liver disease, n (%) 18 (1.9) 44 (0.5) <0.001
Unstable angina, n (%) 265 (28.3) 2330 (27.1) 0.43
NSTEMI, n (%) 92 (9.8) 813 (9.5) 0.71
STEMI, n (%) 140 (15.0) 1445 (16.8) 0.15
Cardiogenic shock, n (%) 23 (2.5) 145 (1.7) 0.09
Congestive heart failure, n (%) 112 (12.0) 856 (10.0) 0.054
Prior cerebrovascular accident, n (%) 21 (2.2) 234 (2.8) 0.39
Prior PCI, n (%) 125 (13.4) 1124 (13.1) 0.81
Prior CABG, n (%) 8 (0.9) 53 (0.6) 0.39
IABP, n (%) 53 (5.7) 397 (4.6) 0.15
Stents placed (≥2), n (%) 278 (29.7) 2329 (27.1) 0.09
Arterial approach 0.27
Radial, n (%) 843 (90.1) 7844 (91.3)
Femoral, n (%) 47 (5.0) 407 (4.7)
Both, n (%) 36 (3.8) 237 (2.8)
Other, n (%) 10 (1.1) 107 (1.2)
Periprocedural medicine
Aspirin, n (%) 903 (96.5) 8449 (98.3) <0.001
Clopidogrel, n (%) 907 (96.9) 8321 (96.8) 0.88
Ticagrelor, n (%) 41 (4.4) 410 (4.8) 0.59
Warfarin, n (%) 12 (1.3) 116 (1.3) 0.87
NOAC, n (%) 3 (0.3) 27 (0.3) 1.0
Tirofiban, n (%) 161 (17.2) 1531 (17.8) 0.64
Enoxaparin, n (%) 254 (27.1) 2448 (28.5) 0.39
TCP: thrombocytopenia; LDL-C: low-density lipoprotein cholesterol; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment
elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; IABP: intra-aortic balloon pump; NOAC:
new oral anticoagulants.
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Controversially, some studies demonstrated opposite
conclusion. Ito et al. [3] evaluated the influence of thrombo-
cytopenia (defined as platelet count < 150 × 109/L) on PCI
patients in the pooled database from 3 prospective studies
in Japan, CREDO- (Coronary Revascularization Demon-
strating Outcome-) Kyoto PCI/CABG registry cohort-2,
RESET (the Randomized Evaluation of Sirolimus-Eluting
Versus Everolimus-Eluting Stent Trial), and NEXT
(NOBORI Biolimus-Eluting Versus XIENCE/PROMUS
Everolimus-Eluting Stent Trial), and demonstrated that even
mild thrombocytopenia at baseline was associated with
higher risk for bleeding events and all-cause death through
a 3-year follow-up (both within and beyond 30 days). Yadav
et al. [15] reported that baseline thrombocytopenia was not
associated with the crude event at 30 days but represented a
hematologic marker of poor prognosis and was strongly
associated with adverse ischemic events 1 year after PCI in
pooled populations from 2 large-scale randomized trials:
the ACUITY (Acute Catheterization and Urgent Interven-
tion Triage Strategy) [16] and HORIZONS-AMI (Harmoniz-
ing Outcomes With Revascularization and Stents in Acute
Myocardial Infarction) [17] trials. More recently, Ayoub
et al.’s study [6] identified patients who underwent PCI with
or without chronic thrombocytopenia from the National
Inpatient Sample database of the UK and revealed that
patients with chronic thrombocytopenia were at higher risk
of in-hospital mortality (OR 2.30, 95% CI 1.90 to 2.70, p <
0:0001) and bleeding complications (OR 2.40, 95% CI 2.05
to 2.72, p < 0:0001).
The contrary scenario can be attributed to the different
cut-off values of platelet count for thrombocytopenia, study





(n = 8595) p
value





Primary outcome: all-cause mortality, bleeding, or
transfusion
37 (4.0) 215 (2.5) 0.009 1.30 (0.88–1.93) 0.19
All-cause mortality 16 (1.7) 93 (1.1) 0.09 1.23 (0.67–2.25) 0.50
Bleeding 14 (1.5) 85 (1.0) 0.15
BARC ≥ 2 12 (1.3) 51 (0.6) 0.014 1.90 (0.98–3.68) 0.06
BARC 1 2 (0.2) 34 (0.4)
BARC 2 6 (0.6) 21 (0.2)
BARC 3a 4 (0.4) 16 (0.2)
BARC 3b 1 (0.1) 9 (0.1)
BARC 3c 0 (0) 3 (0)
BARC 5a 1 (0.1) 2 (0)
Transfusion 18 (1.9) 90 (1.0) 0.016 1.53 (0.88–2.66) 0.13
RBC transfusion 16 (1.7) 79 (0.9) 0.021 1.52 (0.85–2.72) 0.16
Platelet transfusion 1 (0.1) 4 (0.05) 0.99
Plasma transfusion 4 (0.4) 18 (0.2) 0.34
Secondary outcome: MACE or CVA 28 (3.0) 212 (2.5) 0.33 1.03 (0.68–1.57) 0.89
MACE 19 (2.0) 123 (1.4) 0.15 1.14 (0.67–1.94) 0.63
Cardiac mortality 13 (1.4) 85 (1.0) 0.25 1.08 (0.56–2.06) 0.82
Myocardial infarction 3 (0.3) 29 (0.3) 1.0
Target vessel revascularization 3 (0.3) 5 (0.1) 0.042 4.93 (1.13–21.46) 0.03
Stent thrombosis 0 (0) 8 (0.1) 1.0
Ischemic CVA 9 (1.0) 93 (1.1) 0.73 0.83 (0.41–1.65) 0.59
Hemorrhagic CVA 0 (0) 3 (0) 1.0
Length of stay (days) 5 (3–7) 4 (3–6) 0.007 0.01 (-0.01–0.02)& 0.52
PCI: percutaneous coronary intervention; TCP: thrombocytopenia; CI: confidence interval; BARC: Bleeding Academic Research Consortium; RBC: red blood
cell; MACE: major adverse cardiovascular events, including in-hospital cardiac mortality, myocardial infarction, target vessel revascularization, or stent
thrombosis; CVA: cerebrovascular accident. $Adjusted for the propensity score in regressionmodels. &β coefficient (95% CI) of lg10-transformed length of stay.
Table 3: The association between advanced thrombocytopenia
(platelet count ≤ 85 × 109/L) and the occurrence of clinical
outcomes.
Clinical outcomes Adjusted odds ratio (95% CI) p value
Primary outcome 1.67 (1.06–2.65) 0.029
All-cause mortality 1.17 (0.56–2.45) 0.68
Bleeding 1.38 (0.67–2.87) 0.384
BARC ≥ 2 2.35 (1.11–5.00) 0.027
Transfusion 2.16 (1.17–4.00) 0.014
Secondary outcome 1.27 (0.76–2.12) 0.366
CI: confidence interval; BARC: Bleeding Academic Research Consortium.
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population, disease severity, definitions of bleeding criteria,
PCI strategy and antithrombotic regimen, the exclusion of
patients with severe thrombocytopenia from some studies,
and varying follow-up durations. For example, in Ito et al.’s
pooled study of 3 different era researches [3], bare-metal
stent, the first-generation DES, or older antiplatelet agents
(ticlopidine) were used in a large proportion of patients (dif-
ferent from the current PCI practice), and bleeding was
Table 4: The association between thrombocytopenia and the occurrence of in-hospital outcomes in the ACS cohort (n = 5078).





(n = 4581) p
value





Primary outcome: all-cause mortality, bleeding, or
transfusion
27 (5.4) 143 (3.1) 0.007 1.33 (0.82–2.16) 0.25
All-cause mortality 13 (2.6) 59 (1.3) 0.017 1.44 (0.71–2.93) 0.31
Bleeding 12 (2.4) 55 (1.2) 0.024 1.71 (0.88–1.71) 0.12
BARC ≥ 2 11 (2.2) 31 (0.7) 0.001 2.56 (1.24–5.44) 0.011
Transfusion 13 (2.6) 62 (1.4) 0.027 1.44 (0.74–2.82) 0.28
RBC transfusion 13 (2.6) 53 (1.6) 0.006 1.74 (0.88–3.44) 0.11
Platelet transfusion 1 (0.2) 2 (0) 0.69
Plasma transfusion 3 (0.6) 11 (0.2) 0.31
Secondary outcome: MACE or CVA 19 (3.8) 123 (2.7) 0.14 1.10 (0.65–1.86) 0.73
MACE 15 (3.0) 75 (1.6) 0.027 1.34 (0.71–2.53) 0.36
Cardiac mortality 11 (2.2) 55 (1.2) 0.058 1.37 (0.65–2.90) 0.41
Myocardial infarction 3 (0.6) 18 (0.4) 0.74
Target vessel revascularization 1 (0.2) 2 (0) 0.69
Stent thrombosis 0 (0) 4 (0.1) 1.0
Ischemic CVA 4 (0.8) 53 (1.2) 0.63
Hemorrhagic CVA 0 (0) 1 (0) 1.0
Length of stay (days) 5 (3–7) 4 (3–7) 0.017 0.01 (-0.01–0.02)& 0.56
ACS: acute coronary syndrome; TCP: thrombocytopenia; CI: confidence interval; MACE: major adverse cardiovascular events, including in-hospital cardiac
mortality, myocardial infarction, target vessel revascularization, or stent thrombosis; CVA: cerebrovascular accident; BARC: Bleeding Academic Research







no. of events (%)
Primary outcome: all-cause mortality, 
bleeding, or transfusion
4 (9.8) 33 (3.7) 2.10 (0.50–8.83)
0.83
20 (4.9) 195 (2.4) 1.28 (0.74–2.23)
All-cause mortality 3 (7.3) 13 (1.5) 2.67 (0.39–18.23) 0.57 (1.7) 86 (1.1) 1.25 (0.57–2.74)
Bleeding 3 (7.3) 11 (1.2) 6.48 (1.12–37.66) 0.085 (1.2) 80 (1.0) 0.92 (0.36–2.38)
BARC ≥2 3 (7.3) 9 (1.0) 9.7 (1.57–60.4) 0.0251 (0.2) 50 (0.6) 0.22 (0.03–1.69)
Transfusion 1 (2.4) 17 (1.9) 0.42 (0.03–6.60) 0.715 (1.2) 85 (1.0) 0.66 (0.25–1.76)
Secondary outcome: MACE or CVA
4 (9.8) 24 (2.7) 2.67 (0.68–10.48)
0.215 (3.7) 197 (2.4) 0.97 (0.53–1.76)





TCP cohort (n = 936)
non-TCP cohort (n = 8595)
Propensity score adjusted odds ratio (95% CI)
Figure 2: The association between ticagrelor use and the risk of in-hospital outcomes in patients with and without TCP. TCP:
thrombocytopenia; BARC: Bleeding Academic Research Consortium; MACE: major adverse cardiovascular events; CVA: cerebrovascular
accident.
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defined in the Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded arteries trial (GUSTO).
ACUITY and HORIZONS-AMI trials recruited patients with
acute coronary syndromes, excluded all patients with
platelet counts < 100 × 109/L, had more severe disease in the
thrombocytopenia group (100-150 × 109/L), and routinely
used glycoprotein IIb/IIIa inhibitor, which is selective for
bailout use according to the current practice. In our cohort,
we did observe higher bleeding risk with usage of tirofiban
in both thrombocytopenia and nonthrombocytopenia
cohorts, while it is more obvious in the thrombocytopenia
cohort (Supplemental Figure 1), which furtherly confirmed
the higher bleeding effect of the combined use of
glycoprotein IIb/IIIa inhibitor.
In Ayoub et al.’s [6] large cohort study, chronic thrombo-
cytopenia patients (durations of >1 year) were identified by
administrative code at discharge from a claim-based data-
base, not validated by single patients’ blood counts. Thus,
the degree of thrombocytopenia might be more severe and
more caused by malignancy or chronic liver disease and asso-
ciated with poorer outcomes. Moreover, studies reported that
the association between platelet count and long-term mortal-
ity functioned in a U-shaped fashion [18], with both lower
and higher platelet counts associated with a greater mortality
risk. Ito et al.’s study [3] confirmed the U-shaped model. The
retrospective analysis from the Mayo Clinic revealed that a
platelet count of less than 50 × 109/L was considered more
significantly increased bleeding risk [8]. Consistently, in our
study, after adjusting for the propensity scores in a logistic
regression model, we found that advanced thrombocytopenia
was associated with higher risk of the primary outcome.
Thus, special attention should be paid to PCI patients with
advanced/severe thrombocytopenia.
Recently, the Academic Research Consortium for High
Bleeding Risk (ARC-HBR) reported a standardized defini-
tion of HBR (a predicted annual BARC 3 or 5 bleeding
rate of ≥4% or an intracranial hemorrhage risk of ≥1%)
in patients undergoing PCI [19]. Anticipated use of long-
term oral anticoagulation, severe or end-stage chronic kid-
ney disease (eGFR < 30mL/min), hemoglobin < 11 g/dL,
moderate or severe baseline thrombocytopenia
(platelet count < 100 × 109/L), and chronic bleeding diathe-
sis are considered important factors of HBR. Moreover,
low body weight, frailty, heart failure, and dialysis are
listed as risk factors of the HBR criteria for Asian patients
[20]. Our study showed that baseline thrombocytopenia
did not appear to have a clinically significant effect on
in-hospital adverse outcomes among patients who under-
went PCI, while the risk of bleeding was increased in the
ACS subgroup with thrombocytopenia and in thrombocy-
topenia patients with ticagrelor. Given the demonstrated
link between bleeding and increased mortality after PCI
[21, 22], it is important for clinicians to pay close atten-
tion to the risk of postprocedure bleeding in ACS patients
and cautiously use ticagrelor because of its higher bleeding
risk [1, 23, 24]. In our study, a total of 3 patients had
hemorrhagic CVA and all were in the nonthrombocytope-
nia cohort. That means, besides platelet number, clinicians
should also pay attention to the function of platelets and
take other bleeding risk factors, such as other major and
minor HBR criteria, into account comprehensively, and
recommended methods for minimizing bleeding risk,
including favoring the radial access, careful dosing of anti-
thrombotic agents, and prescribing a proton pump inhibi-
tor, should be taken in high bleeding risk patients. Similar
to Eikelboom et al.’s [25] and Yadav et al.’s [15] observa-
tion, other used antithrombotic agent did not have a sig-
nificant effect on the association between baseline
thrombocytopenia and in-hospital adverse clinical events
in our study. This reminds us that baseline thrombocyto-
penia is most probably not a mediator of mortality in
most cases, and less intensive antithrombotic during or
after PCI in patients with baseline thrombocytopenia
may lead to the increase in ischemic events. The higher
odds of TVR in the thrombocytopenia group of our study
may be attributed to its lesser periprocedural prescription
of aspirin. Therefore, we should assess comprehensively
the severity of the atherothrombotic event and the overall
clinical status for prognosis prediction.
4.1. Limitations. This study has several limitations. Firstly,
despite the use of the propensity score approach for control-
ling for possible confounders, the observed results may still
subject to imbalances between patients with or without
thrombocytopenia due to unmeasured confounders, such as
clotting of platelet when collecting blood samples occurring
sometimes in the clinical settings, which may mislead to
thrombocytopenia. Secondly, the causes of baseline throm-
bocytopenia were not investigated in every case, and heparin
or antiplatelet drug administration prehospital could poten-
tially influence platelet counts. However, the hazard of
thrombocytopenia was adjusted with the presentation of
acute myocardial infarction and previous PCI, CABG, and
stroke, which is linked with antiplatelet therapy. Thirdly,
the sample of PCI patients with ticagrelor was relatively small
because ticagrelor only became available in China in recent
years. Prospective randomized studies are needed to provide
robust data. Lastly, we did not explore the long-term effect of
baseline thrombocytopenia, and only nine patients had
severe thrombocytopenia in our study. Thus, future prospec-
tive studies with larger sample size and more patients with
severe thrombocytopenia are required.
5. Conclusions
Although baseline thrombocytopenia was common among
patients who underwent PCI, it did not appear to have a clin-
ically significant effect on in-hospital adverse outcomes.
However, adverse events were increased in patients with
advanced thrombocytopenia. In addition, bleeding risk was
increased in the ACS subgroup with thrombocytopenia and
was significantly higher in thrombocytopenia patients with
ticagrelor. This retrospective single-center study indicated
that it seemed feasible for patients with intermediate throm-
bocytopenia to receive PCI as well as conventional antiplate-
let therapy. Clinicians should pay close attention to the
advanced thrombocytopenia cohort and the risk of
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postprocedure bleeding in ACS patients and cautiously use
potent P2Y12 inhibitor, such as ticagrelor.
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